A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Sponsor: ONL Therapeutics
This PHASE1 trial investigates Rhegmatogenous Retinal Detachment - Macula Off and is currently completed. ONL Therapeutics leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2021 — Nov 2022 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ONL Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .